An antiviral drug that is given to people recently infected with Covid is now set to be trialled in hospitalised patients.
Clinical studies have suggested the drug, which is made by Pfizer and known as Paxlovid, can cut the risk of hospital admission or death by 88 per cent if given in the first five days of symptoms.
